Illustrative image – not actual.Neuland Laboratories, a Hyderabad-based bulk drug company, is setting up two pilot plants, one each at Hyderabad and Bangalore.
The company's project for work on development of corticosteroids has been approved for a Rs.1.5 crore funding by the Department of Science & Technology. Neuland proposes to invest Rs.3 crore in the plants, apart from another Rs.2-3 crore spending in the initial phase.
The corticosteroids manufacturing process involves 30 steps starting from the basic raw materials. Corticosteroids are a group of anti-inflammatory drugs, similar to the corticosteroid hormones produced by the cortex of the adrenal glands, used to treat inflammatory diseases such as asthma, chronic lung disease, rheumatoid arthritis and other connective tissue diseases.
Neuland Laboratories, which started with the manufacture of salbutamol sulphate, has built strong quality and regulatory systems, apart from manufacturing facilities for various bulk drugs. The company has the approval from the US Food and Drug Administration for salbutamol, ranitidine form-I and latanoprost bulk drugs.
Neuland, which has recently started exporting ranitidine bulk drug to the US, hopes to export around six tonnes during 2002. Neuland has recently commercialised ramipril, mitrazapine and olanzapine bulk drugs for the domestic markets.
In order to fund its growth plans, the company proposes to tap the US capital markets with an American depository shares (ADS) issue of $50 million in 2005.
